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Hypertension is a major risk factor of cardiovascular morbid-
ity and the most common cause of congestive heart failure. 
Hypertensive cardiac remodeling is characterized by left ven-
tricular hypertrophy and cardiac fibrosis.1–3 Activation of the 
rennin-angiotensin system plays an important role in blood 
pressure control, cardiovascular regulation and remodeling. 
Angiotensin II (Ang II), a critical hormone of this system, 
has  been  implicated  in  the  development  of  cardiac  fibrosis 
and inflammation. Progressive cardiac fibrosis contributes to 
increased cardiac muscle stiffness, leading to cardiac dysfunc-
tion and heart failure.4 However, the mechanisms of the regu-
lation of cardiac fibrosis and inflammation by Ang II remain to 
be explored.
The  role  of  inflammation  in  fibrosis  has  been  shown  by 
recent studies describing an important role for blood-borne, 
monocytic fibroblast precursors that express CD34 and CD45 
in Ang II–induced or other pathological interstitial cardiac 
fibrosis.5 Ang II infusion resulted in the appearance of bone 
marrow-derived CD34+/CD45+ fibroblast precursor cells that 
expressed collagen type I and the cardiac fibroblast marker 
DDR2,  and  structural  fibroblasts  were  negative  for  CD34/
CD45.6 Moreover, knockout (KO) of monocyte chemoattract-
ant protein 1 prevented Ang II–induced infiltration of CD34+/
CD45+ fibroblast precursor cells and cardiac fibrosis.
Growing evidence indicates that Ang II influences all stages 
of the inflammatory response involved in inflammatory gene 
expression.  Via  its  AT1  receptor,  Ang  II  activates  NADPH 
oxidase and produces reactive oxygen species, thus leading 
to activation of the transcriptional factors Ets-1, early growth 
response  1,  and  nuclear  factor-κB  (NF-κB).  We  previously 
showed that in vascular smooth muscle cells. Ang II activates 
NF-κB via an IKK- and a mitogen-activated protein kinase 
(MAPK)-dependent  mechanism.7–9  However,  how  Ang  II 
activates NF-κB in inflammatory cells remains unknown.
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Background
Angiotensin II (Ang II)–induced cardiac remodeling with the 
underlying mechanisms involving inflammation and fibrosis has 
been well documented. Cytosolic adaptor caspase recruitment 
domain 9 (CARD9) has been implicated in the innate immune 
response. We aimed to examine the role of CARD9 in inflammation 
and cardiac fibrosis induced by Ang II.
methodS
Two-month-old CARD9-deficient (CARD9−/−) and wild-type (WT) 
male mice were infused with Ang II (1,500 ng/kg/min) or saline for 
7 days. Heart sections were stained with hematoxylin and eosin and 
Masson trichrome and examined by immunohistochemistry; and 
activity and protein levels were measured in macrophages obtained 
from mice.
reSultS
WT mice with Ang II infusion showed a marked increase in 
CARD9+ macrophages in the heart, but CARD9−/− mice showed 
significantly suppressed macrophage infiltration and expression 
of proinflammatory cytokines, including interleukin-1β (IL-1β) and 
connective tissue growth factor (CTGF). Importantly, Ang II–induced 
cardiac fibrosis (extracellular matrix and collagen I deposition) 
was diminished in CARD9−/− hearts, as was the expression of 
transforming growth factor-β (TGF-β) and level of myofibroblasts 
positive for α-smooth muscle actin (α-SMA). Furthermore, Ang II 
activation of nuclear factor-κB (NF-κB), jNK and p38 mitogen-
activated protein kinases (MAPKs) in WT macrophages was reduced 
in CARD9−/− macrophages.
concluSion
CARD9 plays an important role in regulating cardiac inflammation 
and fibrosis in response to elevated Ang II.
Keywords: blood pressure; CARD9; cardiac fibrosis; hypertension; 
inflammation; myofibroblast; NF-κB
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The caspase-recruitment domain (CARD) is a protein-bind-
ing module that mediates the assembly of CARD-containing 
proteins.  Cytosolic  adaptor  caspase  recruitment  domain  9 
(CARD9) has received much attention.4,10 It consists of an 
amino-terminal  CARD  and  a  carboxyterminal  coiled-coil 
domain and is closely related to the well-characterized CARD-
containing  adaptor  CARMA1  (also  called  CARD11  and 
Bimp3).4,10 CARD9 is expressed in various tissues, including 
spleen, liver, placenta, lung, leukocytes,4,10 with highest expres-
sion in macrophages and dendritic cells.11 Several studies of 
CARD9-deficient mice demonstrated that CARD9 is involved 
in inducing cytokine activity and in in vivo protection against 
fungal and bacterial infection.11–16 CARD9 has disparate func-
tions in these two pathways, linking tyrosine kinases to activa-
tion of the transcription factor NF-κB and toll-like receptors 
to MAPKs, including p38 and JNK.11,17,18 Although such data 
suggest that CARD9 plays a central role in the innate immune 
response, no studies have examined the effects of CARD9 on 
inflammation and cardiac fibrosis.
Given the role of CARD9 in inflammation, we sought to 
determine the role of CARD9 signaling in Ang II–induced 
inflammation and cardiac fibrosis. We used a mouse model 
with KO of the CARD9 gene and Ang II infusion. Cardiac 
fibrosis and inflammatory response induced by Ang II infu-
sion was markedly inhibited in CARD9−/− mice.
methodS
Animal  model.  CARD9-KO  (CARD9−/−)  mice  were  kindly 
supplied by Dr Lin (Department of Molecular and Cellular 
Oncology,  University  of  Texas,  Houston,  TX).  Two-month-
old  CARD9−/−  mice  and  littermate  wild-type  (WT)  male 
mice  of  the  same  C57BL/6  background  were  used.  Mice 
were implanted with osmotic pumps(Alzet MODEL 1007D; 
DURECT, Cupertino, CA) filled with Ang II and infused at 
1,500 ng/kg/min in Ringer’s solution (0.01 mol/l acetic acid in 
saline). Control mice received infusion of saline of comparable 
volume. WT and CARD9−/− mice were randomly assigned to 
the control group or Ang II–treated group. Systolic blood pres-
sure was measured by the tail-cuff system (Softron BP-98A; 
Softron, Tokyo, Japan), and values were derived from an average 
of 6–8 measurements per animal at each time point. The ani-
mals were handled according to the animal welfare regulations 
of Capital Medical University, Beijing, China, and the study 
protocol was approved by the Animal Subjects Committee of 
Capital Medical University.
Histology and immunohistochemistry. Animals were killed 7 
days after Ang II or saline infusion. Hearts were isolated and 
fixed in 4% paraformaldehyde solution. The samples were cut 
into 5-μm sections and stained with hematoxylin and eosin 
by standard procedures. To measure fibrotic areas, sectioned 
hearts were stained with Masson trichrome. The interstitial 
fibrotic areas were calculated as the ratio of total area of intersti-
tial fibrosis to total area of the section. Immunohistochemical 
analysis involved antibodies against CARD9 (1:200 dilution), 
Mac-2 (1:400 dilution), interleukin-1β (IL-1β) (1:200   dilution), 
connective tissue growth factor (CTGF) (1:200 dilution) and 
transforming growth factor-β (TGF-β) (1:300 dilution; all Santa 
Cruz Biotechnology, Santa Cruz, CA); and   collagen I (1:1,000 
dilution).  Anti-F4/80  (1:100  dilution;  Abcam,  Cambridge, 
MA), which recognizes the mouse F4/80 antigen, a 160 kDa 
glycoprotein expressed a wide range of mature tissue macro-
phages  including  Kupffer  cells,  Langerhans  cells,  microglia, 
macrophages located in the gut lamina propria, peritoneal cav-
ity, lung, thymus, bone marrow stroma, and macrophages in 
the red pulp of the spleen. The macrophages we used in in vitro 
study  were  from  peritoneal  cavity.  α-Smooth  muscle  actin 
(α-SMA) (1:200 dilution) described previously.19 Images were 
viewed and captured by use of a Nikon Labophot 2 microscope 
equipped  with  a  Sony  CCD-Iris/RGB  color  video  camera 
attached to a computerized imaging system and analyzed by 
ImagePro Plus 3.0 (ECLIPSE80i/90i; Nikon, Tokyo, Japan).
Cell culture. Isolation of mouse peritoneal macrophages was as 
described.20 Briefly, 8–10-week-old mice were injected with 
2 ml of 4% thioglycollate medium. Then, 4 days later, mice 
were killed and the peritoneal cavity was flushed with 5-ml 
cold  phosphate-buffered  solution.  The  phosphate-buffered 
solution with macrophages was removed with a syringe, and 
the process was repeated twice. Macrophages from each mouse 
were plated in Dulbecco’s modified Eagle’s medium supple-
mented  with  10%  fetal  bovine  serum  and  1:100  penicillin/
streptomycin. Nonadherent cells were removed after 4 h, and 
the medium was replaced with fresh medium.21
NF-κB luciferase reporter assay. NF-κB transcriptional activ-
ity was measured by use of adenovirus infection with NF-κB 
luciferase  reporter  (Ad.NF-κB-Luc)  as  described.22  Briefly, 
peritoneal macrophages from WT and CARD9−/− mice were 
infected with Ad.NF-κB-Luc at a multiplicity of infection of 5 
for 24 h before 100 nmol/l Ang II treatment; from each sample, 
5 μg total protein underwent luciferase activity assay according 
to the manufacturer’s protocol (Promega, Madison, WI).
Western blot analysis. Cells  were  lyzed  with  lysis  buffer  (20 
mmol/l  Tris  (pH  7.5),  150 mmol/l  NaCl,  1 mmol/l  EDTA, 
1 mmol/l EGTA, 1% Triton X-100, 2.5 mmol/l sodium pyrophos-
phate, 1 mmol/l β-glycerophosphate, 1 mmol/l Na3VO4, 4 μg/ml 
aprotinin, 4 μg/ml leupeptin, 4 μg/ml pepstatin, and 1 mmol/l 
PMSF). Western blot analysis was performed as described.23 
In total, 50 μg cell protein was loaded on 10% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis gels, transferred to 
nitrocellulose membrane, and probed with the primary anti-
bodies against CARD9, β-actin (Santa Cruz Biotechnology), 
phospho-p65  (Ser536),  p65,  phospho-JNK1/2  (Thr183/
Tyr185), JNK1/2, phospho-p38 (Thr180/Tyr182), and p38 (all 
Cell Signaling Technology, Danvers, MA). After being washed 
extensively, the membranes were then incubated with horserad-
ish peroxidase-conjugated secondary antibody for 1 h at room 
temperature. The signals were visualized by use of an enhanced 
chemiluminescence kit (Amersham, Piscataway, NJ). The levels 
of signaling proteins were normalized to that of β-actin.AMERICAN JOURNAL OF HYPERTENSION | VOLUME 24 NUMBER 6 | jUNE 2011   703
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Statistical  analysis.  Data  are  expressed  as  mean  ±  s.e.m. 
Statistical  analysis  involved  one-way  ANOVA  followed  by 
LSD t-test for multiple comparisons within treatment groups. 
Analysis  involved  use  of  SPSS  v13.0  (SPSS,  Chicago,  IL). 
P < 0.05 was considered statistically significant.
reSultS
ang ii infusion stimulates infiltration of card9+  
inflammatory cells into mouse hearts
To investigate the role of CARD9 in the development of Ang 
II–induced cardiac remodeling, WT mice were infused with 
Ang II, 1,500 ng/kg/min, for 7 days. The systolic blood pres-
sure, heart weight/body weight (HW/BW) and heart weight/
tibia length (HW/TL) ratios were measured (Table 1). Baseline 
BP, HW/BW, and HW/TL ratios were similar in both WT and 
KO mice. After Ang II treatment, these parameters tended to 
be increased in KO mice compared with WT mice, but the dif-
ference was not statistically significant. Immunohistochemistry 
revealed  that  Ang  II  infusion  significantly  increased  the 
number of CARD9+ cells in mice hearts as compared with the 
control group (P < 0.05; Figure 1a).
CARD9 is known to be highly expressed in macrophages.11 
We then examined whether CARD9 is expressed in macro-
phages from myocardial tissues or from the peritoneal cavity 
using double immunostaining for F4/80 (for macrophages) and 
CARD9. CARD9 was expressed in macrophages, and its expres-
sion was markedly induced after Ang II infusion (Figure 1b,c).
card9 deficiency inhibits myocardial inflammation  
induced by ang ii in mouse hearts
Inflammatory cell infiltrates were markedly increased in WT 
mice after Ang II infusion as compared with untreated WT mice 
(Figure 2a). The infiltration of inflammatory cells after Ang 
II was lower in CARD9−/− mice than in WT mice (P < 0.05). 
Furthermore,  immunohistochemical  staining  of  myocardial 
sections demonstrated the expression of Mac-2 (macrophage 
marker).  IL-1β  and  CTGF  significantly  increased  in  Ang 
II–treated WT mice as compared with untreated WT mice, 
with the increased expression significantly lower in CARD9−/− 
mice than in WT mice after Ang II infusion (Figure 2b–d). The 
protein expression of Mac-2, IL-1β, and CTGF did not differ 
between WT and CARD−/− mice without Ang II treatment 
(Figure  2b–d).  Moreover,  the  numbers  of  TUNEL-positive 
cardiomyocytes were comparable between WT and KO mice 
  following 7 days of Ang II infusion (data not shown).
card9 deficiency attenuates cardiac fibrosis  
induced by ang ii in mouse hearts
We then determined the role of CARD9 in the development of 
cardiac fibrosis. Systolic blood pressure was markedly increased 
in both WT and CARD9−/− mice after Ang II infusion, with no 
significant difference between WT and CARD9−/− mice (data 
not shown). Moreover, heart sections stained with Masson tri-
chrome for measurement of fibrotic areas showed that Ang II 
infusion significantly increased cardiac fibrotic areas in Ang 
II–treated  WT  mice  as  compared  with  untreated  WT  mice 
(Figure 3a). However, in CARD9−/− mice, the fibrotic areas 
were significantly smaller than in WT mice with Ang II treat-
ment. WT and CARD9−/− mice did not differ in cardiac fibrotic 
areas  without  Ang  II  treatment.  Moreover,  immunohisto-
chemistry confirmed that with Ang II treatment, the increased 
protein levels of collagen I and TGF-β in WT mice were mark-
edly suppressed in CARD−/− mice (Figure 3b,c). With Ang II 
  treatment, the protein expression of α-SMA, a marker of myofi-
broblasts, was markedly elevated in WT mice but significantly 
reduced in CARD−/− mice (P < 0.01; Figure 3d).
effect of card9 on the activation of nF-κB and maPk  
signaling pathways in mouse peritoneal macrophages
To determine the mechanisms of the inhibition of cardiac inflam-
mation and fibrosis in CARD9−/− mice after Ang II   infusion, 
we first examined the CARD9 downstream target NF-κB activ-
ity in peritoneal macrophages using NF-κB luciferase reporter 
assay. Ang II treatment dose-dependently increased NF-κB luci-
ferase activity in WT macrophages (Figure 4a), which was sig-
nificantly suppressed in CARD−/− macrophages.
table 1 | Body weight, systolic BP, hw/Bw and hw/tl ratios
Parameters
WT KO WT + Ang II KO + Ang II
(n = 6) (n = 6) (n = 6) (n = 6)
BP (mm Hg) 97.33 ± 6.03 95.33 ± 4.62 135 ± 10 144 ± 12
HW/BW (mg/g) 5.03 ± 0.35 5.22 ± 0.26 5.74 ± 0.81 6.00 ± 0.77
HW/TL (mg/mm) 7.01 ± 0.4 6.86 ± 0.37 8.12 ± 0.99 9.31 ± 1.82
Ang II, angiotensin II; BP, blood pressure; BW, body weight; HW, heart weight; KO, 
knockout; TL, tibia length; WT, wild type.
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Figure 1 | Angiotensin II (Ang II) infusion induces cytosolic adaptor caspase 
recruitment domain 9 (CARD9) expression in macrophages of cardiac tissues. 
Wild-type (WT) mice were infused with Ang II at 1,500 ng/kg/min for 7 days, 
and heart tissues were harvested. (a) Heart sections from saline- and Ang 
II–treated mice stained with anti-CARD9 antibody (Ab) (left). Bar = 50 μm. 
F4/80 (macrophages) and CARD9 immunofluorescence staining of (b) cardiac 
tissues or (c) peritoneal macrophages from both WT and CARD9−/− mice 
infused with or without Ang II.704     jUNE 2011 | VOLUME 24 NUMBER 6 | AMERICAN JOURNAL OF HYPERTENSION
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We next examined the activation of NF-κB and MAPKs in peri-
toneal macrophages by Western blot analysis. Without Ang II treat-
ment, levels of NF-κB/p65, p38, and JNK1/2 phosphorylation were 
lower in CARD9−/− than WT macrophages (Figure 4b). However, 
Ang II markedly activated NF-κB/p65, p38, and JNK1/2 in WT 
macrophages as compared with untreated WT cells. Activation 
of NF-κB/p65, p38, or JNK1/2 was similar in CARD9−/− macro-
phages before and after Ang II treatment (Figure 4b).
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Figure 2 | Cytosolic adaptor caspase recruitment domain 9 (CARD9) 
deficiency inhibits angiotensin II (Ang II) infusion–induced proinflammatory 
cell infiltration and expression of inflammatory cytokines. (a) Heart sections 
from wild-type (WT) and CARD9−/− mice treated with saline or Ang II 
at 1,500 ng/kg/min for 7 days were stained with hematoxylin and eosin 
(HE). (b–d) Heart sections from WT and CARD9−/− mice were detected by 
immunohistochemistry with antibodies against Mac-2, interleukin-1β (IL-1β), 
and connective tissue growth factor (CTGF) (top). Bar graph shows quantified 
areas (bottom). Bar = 50 μm. Data represent mean ± s.e.m. (n = 5). *P < 0.01 vs. 
WT+Ang II.
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Figure 3 | Cytosolic adaptor caspase recruitment domain 9 (CARD9) 
knockout prevents angiotensin II (Ang II) infusion–induced cardiac 
fibrosis. (a) Representative Masson trichrome staining of heart sections 
from wild-type (WT) and CARD9−/− mice (top). Bar graph shows quantified 
fibrotic areas on histological sections (bottom). (b–d) Heart sections from 
WT and CARD9−/− mice were detected by immunohistochemistry with 
antibodies against collagen I, transforming growth factor-β (TGF-β) and 
α-smooth muscle actin (α-SMA) (top). Bar graph shows quantified areas 
(bottom). Bar = 50 μm. Data were represented as the mean ± s.e.m. (n = 5). 
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diScuSSion
Although Ang II has powerful proinflammatory effects on car-
diac fibrosis and inflammation, the precise molecular mech-
anisms for these effects are not fully understood.24–28 In the 
present study, we found that Ang II significantly stimulated the 
infiltration of CARD9+ macrophages into hearts. Importantly, 
CARD9−/− prevented Ang II–induced inflammation and car-
diac fibrosis. These effects were associated with reduced acti-
vation  of  the  NF-κB/MAPK  signaling  pathway,  expression 
of proinflammatory cytokines and accumulation of α-SMA+ 
myofibroblast  cells  with  Ang  II  infusion.  Thus,  CARD9  is 
important in hypertensive cardiac remodeling induced by Ang 
II infusion.
Cardiac fibrosis and inflammation are the major events of 
Ang II–induced myocardial remodeling. CARD9 is a caspase 
recruitment-domain–containing signaling protein expressed in 
various tissues.10,11 It is closely associated with several inflam-
matory diseases, including tuberculosis, inflammatory bowel 
disease,  tuberculosis,  and  ankylosing  spondylitis.13,29,30  In 
CARD9−/− mice, stimulation of dendritic cells caused a marked 
decrease in the production of IL-2, -6, and -10, and TNF-α and 
decreased numbers of Th17 cells.31–33 Humans with CARD9 
mutation show defects in inflammation responses.34 Given the 
important role of CARD9 in inflammation, we investigated the 
role of CARD9 in cardiac inflammation and fibrosis after Ang II 
infusion. We found infiltrated macrophages expressing CARD9 
in response to Ang II infusion. The critical role of CARD9 was 
demonstrated by Ang II–induced macrophage infiltration, and 
the expression of TGF-β, collagen I, α-SMA, IL-1β, and CTGF 
was significantly inhibited in CARD9−/− mice with Ang II infu-
sion (Figures 2 and 3).
Myofibroblast formation is controlled by a number of growth 
factors, cytokines, and mechanical stimuli.35 In the present 
study, the number of α-SMA+ myofibroblasts in myocardial 
tissues of CARD9−/− mice was significantly lower than that 
of WT mice after Ang II infusion (Figure 3). Moreover, the 
expression of collagen I and TGF-β was markedly decreased 
in CARD9−/− mice (Figure 3). Therefore, CARD9 deficiency 
inhibits cardiac fibrosis by inhibiting myofibroblast formation.
Increasing evidence has demonstrated that Ang II, via its 
type 1 receptor, activates a number of signaling pathways, 
including  reactive  oxygen  species,  MAPKs,  receptor-  or 
nonreceptor-associated tyrosine kinases, and transcriptional 
factors such as NF-κB, Ets-1, and early growth response 1 to 
regulate  cardiac  hypertrophy,  inflammation,  and  fibrosis.36 
Among  these,  NF-κB  and  MAPK  signaling  pathways  play 
  pivotal roles in regulating the inflammatory, immune, and 
apoptotic responses in mammals.37 Ang II, via AT1R acti-
vation, also increases production of aldosterone which is a 
steroid  hormone  with  mineralocorticoid  activity.  Beyond 
its effects on renal sodium reabsorption, aldosterone exerts 
effects on the kidney, blood vessels, and the heart, and plays 
an important role in renal and cardiovascular injury, includ-
ing inflammation, tissue remodeling and fibrosis, has been 
demonstrated in various animal models of hypertension.38,39 
The  aldosterone  increases  tissue  angiotensin-converting 
enzyme  activity  and  upregulates  AT1,  indicating  a  vicious 
forward feedback loop resulting in increased production of 
both Ang II and aldosterone.40–42 Furthermore, Rickard et al. 
demonstrated macrophage-specific KO of mineralocorticoid 
receptors  protected  against  DoCa-induced  cardiac  fibrosis 
and  hypertension.43  However,  question  remains  of  how  is 
proinflammatory  transcriptional  factor  NF-κB  activated  in 
macrophage in response to Ang II.
Interestingly, CARD9 is selectively involved in the activation 
of NF-κB and MAPKs, which is required for the production 
of proinflammatory cytokines in innate immune responses to 
intracellular pathogens.11,44–46 CARD9 signals allow the Toll-
like receptor and Nod2 pathways to induce MAPK activation 
(including p38 and JNK1/2) and tyrosine kinase pathways to 
induce NF-κB activation. In the present study, Ang II treat-
ment resulted in a marked activation of NF-κB and MAPK 
signaling pathways, as demonstrated by increased NF-κB luci-
ferase activity (Figure 4a) and increased levels of phosphor-
ylated NF-κB/p65, p38, and JNK1/2 in macrophages from WT 
mice. In contrast, macrophages from CARD9−/− mice showed 
no  significant  activation  of  NF-κB,  p38,  JNK1/2  with  Ang 
II treatment (Figure 4b). Thus, CARD9 is involved in Ang 
II–mediated regulation of NF-κB and MAPKs in the heart.
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Figure 4 | Effect of cytosolic adaptor caspase recruitment domain 9 (CARD9) 
knockout on the activation of nuclear factor-κB (NF-κB) and mitogen-
activated protein kinases. (a) Peritoneal macrophages were stimulated with 
different concentrations of angiotensin II (Ang II) for 24 h NF-κB activity was 
determined by luciferase assay (n = 3). *P < 0.01 vs. control. (b) Peritoneal 
macrophages were stimulated with 100 nmol/l Ang II for 24 h. The protein 
levels of NF-κB/p65, jNK1/2, p38, and GAPDH were determined by Western 
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In conclusion, we revealed an important role of CARD9 in 
Ang II infusion–induced cardiac remodeling. CARD9 defi-
ciency inhibited inflammatory cells infiltration, expression of 
proinflammatory cytokines, accumulation of myofibroblasts, 
and cardiac fibrosis with Ang II treatment. These effects might 
be a result of inhibiting the activation of NF-κB and MAPKs.
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